• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab.

作者信息

Sabini E, Sframeli A, Marinò M

机构信息

Department of Clinical and Experimental Medicine, Endocrinology Unit I, University of Pisa, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Division of Immunology, Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.

出版信息

J Endocrinol Invest. 2018 Jul;41(7):877-878. doi: 10.1007/s40618-018-0906-0. Epub 2018 May 26.

DOI:10.1007/s40618-018-0906-0
PMID:29804271
Abstract
摘要

相似文献

1
A case of drug-induced Graves' Orbitopathy after combination therapy with Tremelimumab and Durvalumab.曲美木单抗与度伐利尤单抗联合治疗后发生药物性格雷夫斯眼眶病1例。
J Endocrinol Invest. 2018 Jul;41(7):877-878. doi: 10.1007/s40618-018-0906-0. Epub 2018 May 26.
2
Chemotherapy-induced exacerbations of thyroid orbitopathy in a patient with B-cell lymphoma.一名B细胞淋巴瘤患者化疗诱导的甲状腺眼病加重
Orbit. 2018 Aug;37(4):299-302. doi: 10.1080/01676830.2017.1423086. Epub 2018 Jan 4.
3
A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.一例与帕博利珠单抗（可瑞达）治疗相关的格雷夫斯眼病病例。
J AAPOS. 2018 Aug;22(4):310-312. doi: 10.1016/j.jaapos.2018.01.006. Epub 2018 Apr 4.
4
Rapid Development of Graves' Ophthalmopathy After Treatment With Ipilimumab and Recurrence With Pembrolizumab in a Patient With Previously Treated Graves' Disease.一例既往接受过治疗的格雷夫斯病患者在使用伊匹木单抗治疗后格雷夫斯眼病迅速发展，并在使用派姆单抗治疗时复发
J Oncol Pract. 2018 Dec;14(12):747-749. doi: 10.1200/JOP.18.00442.
5
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.特利木单抗联合度伐鲁单抗治疗间皮瘤患者（NIBIT-MESO-1）：一项开放标签、非随机、Ⅱ期研究。
Lancet Respir Med. 2018 Jun;6(6):451-460. doi: 10.1016/S2213-2600(18)30151-6. Epub 2018 May 15.
6
[Novel treatment opportunities in Graves' orbitopathy].[格雷夫斯眼眶病的新型治疗机遇]
Orv Hetil. 2014 Aug 17;155(33):1295-300. doi: 10.1556/OH.2014.29963.
7
Novel treatment modalities for Graves' orbitopathy.格雷夫斯眼眶病的新型治疗方式。
Pediatr Endocrinol Rev. 2010 Mar;7 Suppl 2:210-6.
8
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.一项关于度伐鲁单抗（MEDI4736）联合或不联合曲美木单抗用于既往接受过治疗的晚期非小细胞肺癌患者的III期研究：ARCTIC研究的原理与方案设计。
Clin Lung Cancer. 2016 May;17(3):232-236.e1. doi: 10.1016/j.cllc.2016.03.003. Epub 2016 Mar 17.
9
Onartuzumab ineffective in non-small-cell lung cancer.奥那珠单抗对非小细胞肺癌无效。
Lancet Oncol. 2017 Feb;18(2):e66. doi: 10.1016/S1470-2045(16)30680-5. Epub 2016 Dec 23.
10
Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma.肺腺癌化疗后发生的肿瘤溶解综合征和获得性鱼鳞病。
J Clin Oncol. 2011 Dec 10;29(35):e859-60. doi: 10.1200/JCO.2011.36.8175. Epub 2011 Oct 31.

引用本文的文献

1
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review.与免疫检查点抑制剂相关的眼部不良事件：一项范围综述
J Ophthalmic Inflamm Infect. 2023 Feb 22;13(1):5. doi: 10.1186/s12348-022-00321-2.
2
Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms.度伐利尤单抗致非小细胞肺癌患者甲状腺炎：病例报告及发病机制探讨。
BMC Endocr Disord. 2022 Nov 22;22(1):291. doi: 10.1186/s12902-022-01190-5.
3
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

本文引用的文献

1
Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.格雷夫斯眼眶病、特发性眼眶炎性假瘤与爱泼斯坦-巴尔病毒感染：一项血清学及分子学研究
J Endocrinol Invest. 2017 May;40(5):499-503. doi: 10.1007/s40618-016-0587-5. Epub 2016 Dec 16.
2
Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis.格雷夫斯病治疗方案与格雷夫斯眼病病程的关系：一项系统评价和荟萃分析。
J Endocrinol Invest. 2016 Nov;39(11):1225-1233. doi: 10.1007/s40618-016-0484-y. Epub 2016 May 24.
3
Combination cancer immunotherapy and new immunomodulatory targets.
免疫检查点抑制剂相关的眼部不良事件：对其机制、诊断和管理的当前认识
Int J Ophthalmol. 2022 Apr 18;15(4):646-656. doi: 10.18240/ijo.2022.04.19. eCollection 2022.
4
Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.西仑吉肽，一种 αvβ3 整合素抑制剂，可增强抗程序性细胞死亡蛋白-1 治疗在小鼠黑色素瘤模型中的疗效。
Bioengineered. 2022 Feb;13(2):4557-4572. doi: 10.1080/21655979.2022.2029236.
5
Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.肺癌免疫检查点抑制剂相关的眼部免疫相关不良事件。
Front Immunol. 2021 Aug 24;12:701951. doi: 10.3389/fimmu.2021.701951. eCollection 2021.
6
Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review.免疫检查点抑制剂的神经眼科并发症：一项系统综述
Eye Brain. 2020 Nov 3;12:139-167. doi: 10.2147/EB.S277760. eCollection 2020.
7
Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).免疫检查点抑制剂的内分泌和代谢不良反应：概述（内分泌学家应该知道什么）。
J Endocrinol Invest. 2019 Jul;42(7):745-756. doi: 10.1007/s40618-018-0984-z. Epub 2018 Nov 23.
联合癌症免疫疗法和新的免疫调节靶点。
Nat Rev Drug Discov. 2015 Aug;14(8):561-84. doi: 10.1038/nrd4591.
4
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.转移性黑色素瘤患者中细胞毒性T淋巴细胞相关抗原4阻断：葡萄膜炎的一个新病因
J Immunother. 2004 Nov-Dec;27(6):478-9. doi: 10.1097/00002371-200411000-00008.